Hyperion Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Hyperion is currently developing Ravicti™ (glycerol phenylbutyrate), formerly known as HPN-100, for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd’s worldwide rights to BUPHENYL® and, subject to certain conditions, AMMONUL®. Hyperion is led by a seasoned executive team with extensive experience developing and commercializing specialty pharmaceutical products.
Looking for a particular Hyperion Therapeutics, Inc employee's phone or email?
Hyperion Therapeutics, Inc Questions
The Hyperion Therapeutics, Inc annual revenue was $113.6 million in 2026.
Hyperion Therapeutics, Inc is based in Brisbane, California.
The NAICS codes for Hyperion Therapeutics, Inc are [32, 32541, 325, 325412, 3254].
The SIC codes for Hyperion Therapeutics, Inc are [283, 28].
Related Companies
